论文部分内容阅读
高血压、糖尿病、血脂异常患者是心脑血管疾病一级预防的高危人群,动脉粥样硬化病变是其共同病生理基础,而后者又是内皮炎性反应、氧化应激、血小板激活等多环节相互作用的结果[1]。作为心脑血管病一级预防综合治疗的重要组成部分,阿司匹林近年来被证实可干预或阻断动脉粥样硬化进程的多个环节,这些作用不局限于经典的抗血小板机制,而且还涉及血小板以外的细胞和组织。目前阿司匹林对心脑血管病一级防御、特别是对糖尿病患者的临床获益虽有争议,但不应忽
Patients with hypertension, diabetes mellitus, and dyslipidemia are at high risk of primary prevention of cardiovascular and cerebrovascular diseases. Atherosclerotic lesions are the common basis of their common diseases, and the latter are the links of endothelium inflammatory reaction, oxidative stress and platelet activation The result of the interaction [1]. As an important part of the comprehensive treatment of primary prevention of cardiovascular and cerebrovascular diseases, aspirin has been proved in recent years to intervene or block atherosclerotic progression in many aspects, these effects are not limited to the classic anti-platelet mechanism, but also to platelets Other than cells and tissues. At present, aspirin for cardiovascular disease a defensive, especially for the clinical benefit of diabetic patients although controversial, but should not suddenly